Premium
Interleukin‐6 (IL‐6) Does Not Change the Expression of Bcl‐2 Protein in the Prevention of Cisplatin‐Induced Apoptosis in Ovarian Cancer Cell Lines
Author(s) -
Ishioka Shinichi,
HaaftenDay Caroline,
Sagae Satoru,
Kudo Ryuichi,
Hacker Neville F.
Publication year - 1999
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.1999.tb01117.x
Subject(s) - apoptosis , cisplatin , dna fragmentation , ovarian cancer , medicine , cancer research , monoclonal antibody , microbiology and biotechnology , cell culture , fragmentation (computing) , cytokine , programmed cell death , andrology , cancer , antibody , immunology , biology , chemotherapy , biochemistry , ecology , genetics
Objective: To study whether interleukin‐6 (IL‐6) changes the expression of the anti‐apoptic Bcl‐2 protein in the prevention of cis ‐diaminedichloroplatinum (II) (CDDP)‐induced apoptosis of human ovarian cancer cells. Methods: Comparative studies were performed on 3 ovarian cancer cell lines after 48 hours of exposure to 0.5–50 ng/m/ IL‐6, 2 μg/m/ anti‐IL‐6 monoclonal antibody (anti‐IL‐6 mAb), 10 μm CDDP, 10 μm CDDP + 0.5–50 ng/m/ IL‐6, and 10 μm CDDP + 2 μg/m/ anti‐IL‐6 mAb. Apoptosis was measured morphologically and by a DNA fragmentation assay. Bcl‐2 protein levels were measured by an ELISA. Results: An increase in apoptosis was observed for each cell line after 48 hours of exposure to 10 μm CDDP. Although high doses of IL‐6 decreased the percentage of apoptotic cells, this cytokine did not change the expression of the Bcl‐2 protein. Conclusion: CDDP‐induced apoptosis was negatively controlled by IL‐6. However, the anti‐apoptic Bcl‐2 protein level was not changed by IL‐6 in the process of apoptosis in the ovarian cancer cell lines.